National Data Bank for Rheumatic Disease (NDB) Registry Study of Safety in Rheumatoid Arthritis (RA) Patients Treated With Certolizumab Pegol (CZP; Cimzia®) and Non-biologic Disease-modifying Antirheumatic Drug (DMARD) Therapies
Observational Model: Cohort, Time Perspective: Prospective
Number of participants with lymphoma
Number of participants with lymphoma during the observational period (up to 6 years)
Frederick Wolfe, M.D.
National Data Bank for Rheumatic Disease
United States: Institutional Review Board